13:38:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-03-04 Bokslutskommuniké 2024
2024-11-05 Kvartalsrapport 2024-Q3
2024-08-13 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning CMOTEC B 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-03-05 Bokslutskommuniké 2023
2023-10-17 Kvartalsrapport 2023-Q3
2023-08-15 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-17 Ordinarie utdelning CMOTEC B 0.00 SEK
2023-05-16 Årsstämma 2023
2023-03-07 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-16 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-03 Kvartalsrapport 2022-Q1
2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian ChemoTech är ett forsknings- och utvecklingsbolag som har tagit fram teknologin Tumörspecifik Elektroporation – TSE™ för behandling av olika cancerformer. Teknologin innebär att man skickar elektroniska pulser till det behandlade området och öppnar tumörcellernas membran för att nå deras DNA. Utöver sin verksamhet i Sverige är bolaget även aktivt i Sydostasien och Indien. Scandinavian ChemoTech grundades 2015 och har sitt huvudkontor i Lund.
2022-08-30 08:30:00

Vetiqure AB has today signed an exclusive distributor agreement with Hasvet Medikal AS "Hasvet", which is the market leader in veterinary medicine in Turkey.

Turkey, with its 84 million inhabitants, is one of Europe's absolute largest markets and thus has a very large potential despite the strained economic situation of the country. There are approximately 4 million cats and 2.5 million dogs in the country.

Hasvet, which is basically a company that was started and is now run by veterinarians, has grown at a rapid pace and is today the major market leader of medical technology in veterinary medicine in the country. Hasvet is also active in several other countries in the Middle East, although this distributor agreement initially only concerns Turkey. According to Hasvet, the establishment of cancer treatments carried out in clinics in Turkey is considerably lower than in north of Europe. This is, however, something that Hasvet has as a goal; to raise awareness of cancer detection and treatment in clinics, as they have done in other areas. The Hasvet group employs almost 300 people, 55 of whom are veterinarians.

"We at Hasvet are happy to start cooperating with Vetiqure AB. Since the first day we were established, selling products and making a profit has always been in the background. Our main goal is to be a cure for animals, our dear friends. We are a company that grows with its collaborators, with help of their innovative products. We hope our cooperation will continue to increase in coming years." - says Murat Güç, Assistant General Manager Hasvet

"The negotiations with Hasvet have been going on for almost 6 months and we are happy that we have now created the conditions to introduce vetIQure™ and TSE to the veterinary market in Turkey. Although we have high hopes for a quick establishment, we must be humble about the time it will actually take as the treatment is new to the Turkish market, but if there is a company with the right capacity and the right skills for a quick and successful establishment, then it Hasvet." - says Mohan Frick, CEO Scandinavian ChemoTech

About Hasvet

Hasvet was founded in 1996 with the aim of importing, selling and reselling services of veterinary medical devices. Over the years, we have never deviated from our focus on animal health. We have always offered innovative and creative products to veterinarians for animal health purposes. Hasvet's market share on the Turkish veterinary market is, according to Hasvet, 80%.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-08-2022 08:30 CET.